Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses. Novartis...

After an unceremonious exit from the COVID-19 vaccine race, Merck & Co. has been sizing up opportunities to lend its expertise to the fight. Now, ...

In the kinase inhibitor class of breast cancer drugs, Pfizer’s Ibrance has held a strong lead in market share—and sales—over Eli Lilly’...

After inking a slate of geography-specific product selloffs last year, Takeda has turned back to Japan. Takeda locked up a deal to sell four Type 2 diabetes meds i...

Just weeks after Aurinia Pharmaceuticals bagged its first FDA green light, the company is turning to one of its clinical manufacturing partners to help brin...

AbbVie’s Rinvoq just recently reported a pivotal trial win in ulcerative colitis, and one team of analysts is already drawing a rosy future for the next-gen immunolo...

The COVID-19 pandemic derailed plans for companies worldwide last year, but Eli Lilly adapted by developing medicines against the novel coronavirus—to the tune of $8...

Sanofi and Regeneron’s Libtayo is on a roll with its second FDA nod in just two weeks. And the latest green light breaks the PD-1 inhibitor out of its skin cancer co...

Novo Nordisk’s Ozempic is already ducking it out with Eli Lilly’s Trulicity in the once-weekly diabetes treatment field. But looming competition from the Indianapoli...

Johnson & Johnson has been battling for years against lawsuits claiming its talc powders cause cancer, but now investors are getting a sense of what the litigati...